Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/8/2025

Management of Percutaneous Nephrostomy and Ureteral Stent Infections

Key Management Principles

  • The American College of Physicians recommends starting with appropriate antimicrobial therapy targeting expected uropathogens before deciding on device management, with a strength of evidence based on clinical guidelines 1, 3
  • The Infectious Diseases Society of America suggests using ceftriaxone or ampicillin/sulbactam as first-line therapy for infected ureteral stents and PCNTs, which has decreased serious post-procedural sepsis-related complications from 50% to 9% in high-risk patients, with a moderate strength of evidence 1, 3
  • The American Journal of Kidney Diseases recommends obtaining blood and urine cultures prior to initiating empiric antibiotics, then adjusting therapy according to culture sensitivities, with a high strength of evidence 4, 2

When to Exchange or Remove the Device

  • The Clinical Infectious Diseases journal suggests that mandatory removal/exchange situations include persistent bacteremia or fungemia despite 48-72 hours of appropriate antimicrobial therapy, with a high strength of evidence 2
  • The American Journal of Kidney Diseases recommends removing or exchanging the device promptly in cases of hemodynamic instability or septic shock, with a moderate strength of evidence 2, 5
  • The Clinical Infectious Diseases journal recommends considering device salvage with antibiotics alone when there is an uncomplicated infection with clinical improvement on antibiotics, with a low strength of evidence 2

Prevention Strategies

  • The Ca-A Cancer Journal for Clinicians recommends periodically reassessing the need for the device and removing when no longer necessary, as infection risk correlates directly with duration of placement, with a moderate strength of evidence 1, 3
  • The American College of Physicians suggests using preprocedural antimicrobial prophylaxis with ceftriaxone or ampicillin/sulbactam for elective PCNT and ureteral stent placement or exchange, with a high strength of evidence 1

REFERENCES